British Peripheral Nerve Society

This meeting is open to BPNS members and other professionals working in relevant areas, but not to patients or members of the general public without advance permission.
BPNS members wishing to register for the meeting may benefit from a reduced registration fee if they log in to the website first.

BPNS Autumn Meeting 2021: virtual

Start Date

End Date

Friday 24 Sep 2021 10:00 AM

Friday 24 Sep 2021 16:30 PM

Location

Zoom meeting hosted by St George's

Details

Virtual places will be limited to 100 and available on a first come first served basis. The costs are below are for virtual attendees; if you wish to attend in person please select the F2F meeting to register.

There are only 50 F2F spaces at higher prices: £35 ordinary members, £15 associate (and retired) members, £50 non-members.

Abstracts

We encourage delegates to submit abstracts through the website for presentation at the meeting. Abstracts may be presented in person or virtually. The abstract deadline is Friday 3rd September.

Please use the link for the F2F meeting to submit abstracts, even if planning to present virtually.

Programme:

Please see the F2F meeting on the website for the full timetable.

Queen Square Annual Update in Neuromuscular Disorders

This course will be held from Wednesday 13th May to Friday 15th May in the Clinical Neuroscience Lecture Theatre, Lower ground, 33 Queen Square, London WC1N 3B

DETAILS/REGISTRATION

Brain Fellowships

Applications are invited for 1 year fellowships funded by the Guarantors of Brain. These fellowships provide bridging salary support to early career clinicians based in the UK prior to obtaining a research fellowship. Further details can be found HERE

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

GWAS study of CIDP

Members are encouraged to participate in a genome-wide association study of CIDP. Brief details can be found HERE

More news »

Meetings

Queen Square Annual Update in Neuromuscular Disorders

Brain Fellowships

New NHSE commissioning policies for rituximab and IVIg

GWAS study of CIDP